Catalent to Acquire Gene Therapy Leader, Paragon Bioservices, Inc.

Catalent, the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, announced they have entered into a definitive agreement under which Catalent will acquire Paragon.

Paragon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors.

For over 25 years, Paragon has partnered with some of the world’s best biotech and pharma companies to develop and manufacture products based on transformative technologies, including AAV and other gene therapies, next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic proteins, and other complex biologics.

Catalent. More products. Better treatments. Reliably supplied.™

Every molecule has a challenge.
We have a solution.

Call: +1 888 SOLUTION
Email: solutions@catalent.com
Visit: catalent.com

Catalent,biologics,adeno-associated virus vectors,gene therapies,drug substance manufacturing,drug product manufacturing,fill/finish,AAV,triple transfection,baculovirus,HSV-based expression,viral vector manufacturing,acquisition,mergers and acquisitions,Paragon Bioservices,